Implantation of XEN‑45 for Treatment of Refractory Secondary Glaucoma - Takeaways - MDSpire

Implantation of XEN‑45 for Treatment of Refractory Secondary Glaucoma

  • By

  • Kun Lv

  • Zhiqiao Liang

  • Kuankuan Wu

  • Yao Ma

  • Kangyi Yang

  • Wenbo Liu

  • Huijuan Wu

  • November 14, 2025

  • 0 min

Share

  • 1

    Secondary glaucoma (SG) arises from various causes leading to elevated intraocular pressure and can progress to glaucomatous optic neuropathy if untreated.

  • 2

    XEN-45 Gel Stent is a minimally invasive option for lowering intraocular pressure in refractory secondary glaucoma, approved by the FDA in 2016.

  • 3

    The study evaluates XEN-45 gel stent implantation in a diverse range of refractory SG cases, including uveitic and steroid-induced glaucoma.

  • 4

    Patients eligible for the study had uncontrolled IOP or required multiple anti-glaucoma medications, with at least 6 months of follow-up.

  • 5

    Surgical techniques for XEN-45 implantation included ab externo methods, chosen based on conjunctival conditions rather than glaucoma severity.

Original Source(s)

Implantation of XEN‑45 for Treatment of Refractory Secondary Glaucoma

  • by Kun Lv, Zhiqiao Liang, Kuankuan Wu, Yao Ma, Kangyi Yang, Wenbo Liu, Huijuan Wu

  • November 14, 2025

Related Content

FOXC1 Duplications Linked to Early-Onset Glaucoma

FOXC1 duplications were the second most common monogenic finding among genetically solved juvenile open-angle glaucoma cases in one registry, supporting the use of copy-number variant analysis in early-onset glaucoma testing.

FDA Clears Nocturnal IOP Device

Balance Ophthalmics gains FDA 510(k) clearance for wireless FSYX glaucoma device

  • May 26, 2026

  • 2 min
Women in Glaucoma: Panelists

  • May 1, 2026

  • 1 min